US, Indian officials meet to discuss drug safety

Feb. 17, 2014

India and the United States have been locked in a regulatory conflict over generic pharmaceutical products distributed on the U.S. market.

India and the United States have been locked in a regulatory conflict over generic pharmaceutical products distributed on the U.S. market. The Food and Drug Administration (FDA) has been tightening its grip on Indian manufacturers, resulting in import bans on a number of products produced by big Indian companies, the Wall Street Journal reports.

The ban that had the most serious implications for the market was the enforcement action taken against Ranbaxy. According to FDA officials, one of its facilities failed to meet the best industry standards and workers at the plant repeatedly manipulated test results. The import ban is just a measure aiming to ensure U.S. consumers are protected, the federal agency claimed.

RELATED: Novo Nordisk locked in legal battle over generic drug

But Indian authorities do not seem to share this opinion. Both drug makers and officials have claimed that their pharmaceutical production was safe and noted that the FDA paid too much attention to "minor flaws" in the process. Some Indian industry representatives have even stated that the FDA was trying to keep cheaper generic products away from the U.S. market for commercial reasons.

In a meeting to discuss the matter, FDA Commissioner Margaret Hamburg and Indian trade minister Anand Sharma talked about safety standards in the pharmaceutical industry, the Wall Street Journal said. Commenting after the meeting, FDA spokeswoman Erica Jefferson said that U.S. officials were not trying to block Indian drug makers' access to the American market and pointed out that the agency was fully aware of the fact that most Indian producers were compliant with the manufacturing requirements.

Sponsored Recommendations

2024 Manufacturing Trends — Unpacking AI, Workforce, and Cybersecurity

The world of manufacturing is changing, and Generative AI is one of the many change agents. The 2024 State of Smart Manufacturing Report takes a deep dive into how Generative ...

State of Smart Manufacturing Report Series

The world of manufacturing is changing, and Generative AI is one of the many change agents. The 2024 State of Smart Manufacturing Report takes a deep dive into how Generative ...

Trying to Keep Pace with Supply Chain Disruption?

CPG manufacturers are struggling to keep up with supply chain disruptions. Learn how to build more resilient operations –and reduce demand shock.

Mitigating Cybersecurity Threats – Step-by-Step

Distributor Wesco adds services focused on identifying and solving OT network and security vulnerabilities in critical manufacturing.